MIGALASTAT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H13NO4
Molecular Weight	163.1717
Optical Activity	( + )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MIGALASTAT

Structure Search

SMILES

OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

InChI

InChIKey=LXBIFEVIBLOUGU-DPYQTVNSSA-N

InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C6H13NO4
Molecular Weight	163.1717
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:20:56 UTC 2023` Edited by `admin` on `Sat Dec 16 16:20:56 UTC 2023`
Record UNII	C4XNY919FW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIGALASTAT

Official Name

English

(2R,3S,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol

Systematic Name

English

MIGALASTAT [MI]

Common Name

English

migalastat [INN]

Common Name

English

Migalastat [WHO-DD]

Common Name

English

MIGALASTAT [USAN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A16AX14

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

NCI_THESAURUS

C87006

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

Code System Code Type Description

CAS

108147-54-2

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

PUBCHEM

176077

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

RXCUI

2054252

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

ChEMBL

CHEMBL110458

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

MERCK INDEX

m11983

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

EVMPD

SUB177094

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

DRUG BANK

DB05018

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

FDA UNII

C4XNY919FW

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

SMS_ID

100000162983

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

DRUG CENTRAL

5110

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

LACTMED

Migalastat

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

USAN

ZZ-100

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

INN

8700

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

DAILYMED

C4XNY919FW

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

NCI_THESAURUS

C78120

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

EPA CompTox

DTXSID201022520

Created by admin on Sat Dec 16 16:20:57 UTC 2023 , Edited by admin on Sat Dec 16 16:20:57 UTC 2023

PRIMARY

Related Record Type Details


					C4XNY919FW

EXCRETED UNCHANGED

Comments:

In urine, unchanged migalastat accounted for 80% of the radioactivity, which equates to 62% of the administered dose.

Qualification:

URINE

Amount:


					CLY7M0XD20

MIGALASTAT HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:


					A790PRZ4Y7

ALPHA GALACTOSIDASE A, HUMAN

TARGET -> INHIBITOR

Interaction Type:

BINDING

Qualification:

IC50

Amount:

Related Record Type Details


					C4XNY919FW

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				ORAL ADMINISTRATION